Related Experiment Video
Updated: Mar 3, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
AMPD3 is associated with the malignant characteristics of gastrointestinal stromal tumors
Meihong Wong1, Kohei Funasaka1, Tomohiko Obayashi1
1Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Abstract:
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract. It is well known that activating mutations in the receptor tyrosine kinases KIT and platelet-derived growth factor receptor-α have essential roles in the pathogenesis of GISTs. The activation of these receptor protein kinases triggers multiple signaling pathways that promote cell proliferation and survival; however, the exact mechanism by which the activation of these kinases promotes the progression of GISTs remains uncertain. The aim of the present was to search for genes that are associated with the progression of GIST. The present study used reverse transcription-quantitative polymerase chain reaction to demonstrate that adenosine monophosphate deaminase 3 (AMPD3) was highly expressed in GISTs. Furthermore, transfection of GIST-T1 cells with KIT-specific small interfering RNA (siRNA) demonstrated that the expression of AMPD3 was dependent on KIT expression, while the depletion of AMPD3 in human GIST-T1 cells using AMPD3-specific siRNA resulted in the suppression of cell migration and invasion. In addition, AMPD3 depletion sensitized GIST-T1 cells to the tyrosine kinase inhibitor imatinib. The results of the present suggested that the combined inhibition of tyrosine kinases and AMPD3 may be effective for the treatment of GISTs.
Insights
Adenosine monophosphate deaminase 3 (AMPD3) is highly expressed in gastrointestinal stromal tumors (GISTs) and drives their progression. Inhibiting AMPD3 alongside tyrosine kinases may offer a new GIST treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms driven by activating mutations in KIT or PDGFRA.
- KIT and PDGFRA signaling pathways promote GIST cell proliferation and survival, but precise progression mechanisms remain unclear.
Purpose of the Study:
- To identify genes associated with GIST progression.
- To investigate the role of adenosine monophosphate deaminase 3 (AMPD3) in GIST pathogenesis and its relationship with KIT signaling.
Main Methods:
- Gene expression analysis using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
- Gene silencing using small interfering RNA (siRNA) targeting KIT and AMPD3 in GIST-T1 cells.
- Assessment of cell migration, invasion, and sensitivity to imatinib.
Main Results:
- AMPD3 was found to be highly expressed in GISTs.
- AMPD3 expression was dependent on KIT expression.
- AMPD3 depletion suppressed GIST cell migration and invasion and sensitized cells to imatinib.
Conclusions:
- AMPD3 plays a significant role in GIST progression, mediated by KIT signaling.
- Combined inhibition of tyrosine kinases and AMPD3 presents a potential therapeutic strategy for GIST treatment.

